MX2021004403A - Virus vaccinia mutantes y uso de los mismos. - Google Patents

Virus vaccinia mutantes y uso de los mismos.

Info

Publication number
MX2021004403A
MX2021004403A MX2021004403A MX2021004403A MX2021004403A MX 2021004403 A MX2021004403 A MX 2021004403A MX 2021004403 A MX2021004403 A MX 2021004403A MX 2021004403 A MX2021004403 A MX 2021004403A MX 2021004403 A MX2021004403 A MX 2021004403A
Authority
MX
Mexico
Prior art keywords
recombinant
expression
resistant
another embodiment
virions
Prior art date
Application number
MX2021004403A
Other languages
English (en)
Spanish (es)
Inventor
Xiaotong Song
Mariya Viskovska
Medaglia Maria Luiza Gomes
Original Assignee
Icellkealex Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icellkealex Therapeutics Llc filed Critical Icellkealex Therapeutics Llc
Publication of MX2021004403A publication Critical patent/MX2021004403A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021004403A 2018-10-22 2019-10-21 Virus vaccinia mutantes y uso de los mismos. MX2021004403A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749102P 2018-10-22 2018-10-22
US201962912344P 2019-10-08 2019-10-08
PCT/US2019/057134 WO2020086423A1 (en) 2018-10-22 2019-10-21 Mutant vaccinia viruses and use thereof

Publications (1)

Publication Number Publication Date
MX2021004403A true MX2021004403A (es) 2021-10-22

Family

ID=70331869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004403A MX2021004403A (es) 2018-10-22 2019-10-21 Virus vaccinia mutantes y uso de los mismos.

Country Status (10)

Country Link
US (1) US20210388388A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870217A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022508942A (cg-RX-API-DMAC7.html)
KR (1) KR20210108944A (cg-RX-API-DMAC7.html)
CN (1) CN113347993A (cg-RX-API-DMAC7.html)
AU (1) AU2019367965A1 (cg-RX-API-DMAC7.html)
CA (1) CA3117378A1 (cg-RX-API-DMAC7.html)
IL (1) IL282509A (cg-RX-API-DMAC7.html)
MX (1) MX2021004403A (cg-RX-API-DMAC7.html)
WO (1) WO2020086423A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
EP4299729A4 (en) * 2021-02-26 2025-06-11 SillaJen, Inc. ONCOLYTIC VIRUS AND USE THEREOF
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN113322279A (zh) * 2021-06-18 2021-08-31 苏州工业园区唯可达生物科技有限公司 一种敲除d8l基因的重组痘苗病毒载体
CN113481240A (zh) * 2021-06-18 2021-10-08 苏州工业园区唯可达生物科技有限公司 一种敲除l1r基因的重组痘苗病毒载体
CN113481241A (zh) * 2021-06-18 2021-10-08 苏州工业园区唯可达生物科技有限公司 一种敲除h3l基因的重组痘苗病毒载体
CN113322280A (zh) * 2021-06-18 2021-08-31 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058643A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058645A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
CN114058644A (zh) * 2021-06-22 2022-02-18 苏州工业园区唯可达生物科技有限公司 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
CN114369587B (zh) * 2021-12-25 2024-03-15 苏州瀚源新酶生物科技有限公司 牛痘病毒加帽酶突变体、重组载体、重组工程菌及其应用
KR102983542B1 (ko) * 2022-06-29 2026-06-30 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
CN116179654B (zh) * 2022-12-30 2023-09-15 军事科学院军事医学研究院环境医学与作业医学研究所 一种检测水中镉离子的滚环扩增检测体系及其应用
CN116990507B (zh) * 2023-06-29 2025-07-08 深圳市新产业生物医学工程股份有限公司 一种用于猴痘病毒感染的早期筛查的方法
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
WO2026107113A1 (en) 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US165477A (en) * 1875-07-13 Improvement in smelting-furnaces
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
JP4344805B2 (ja) * 2000-07-07 2009-10-14 独立行政法人科学技術振興機構 遺伝子組換えワクシニアウイルスワクチン
JP4802401B2 (ja) * 2000-11-07 2011-10-26 トランスジェン・ソシエテ・アノニム 標的化感染特異性を有するポックスウイルス
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
US7393533B1 (en) * 2004-11-08 2008-07-01 La Jolla Institute For Allergy And Immunology H3L envelope protein immunization methods and H3L envelope passive protection methods
US7521195B1 (en) * 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
US7807180B2 (en) * 2007-08-21 2010-10-05 University Of Massachusetts Poxvirus methods and compositions
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
IN2012DN02692A (cg-RX-API-DMAC7.html) * 2009-11-05 2015-09-04 Ct Molecular Med & Immunology
FI20115914L (fi) * 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
CA3029106A1 (en) * 2016-06-28 2018-01-04 Universitat Ulm Complement inhibitors and uses thereof
MY200887A (en) * 2016-08-19 2024-01-22 Sementis Ltd Viral Vaccines

Also Published As

Publication number Publication date
CN113347993A (zh) 2021-09-03
JP2022508942A (ja) 2022-01-19
US20210388388A1 (en) 2021-12-16
AU2019367965A1 (en) 2021-06-03
EP3870217A1 (en) 2021-09-01
KR20210108944A (ko) 2021-09-03
WO2020086423A1 (en) 2020-04-30
CA3117378A1 (en) 2020-04-30
IL282509A (en) 2021-06-30
EP3870217A4 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
Andrei et al. Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma-and papillomaviruses and non-viral induced neoplasia
MX2020013723A (es) Anticuerpos que toman como diana la glicoproteina 120 (gp120) del virus de inmunodeficiencia adquirida (vih) y metodos de uso.
MY196224A (en) Human Antibodies To Ebola Virus Glycoprotein
EA201891021A1 (ru) Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
EA202191418A1 (ru) Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
Samandary et al. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine
MX2017008173A (es) Terapias de combinacion con cepas de listeria recombinantes.
MY185320A (en) Human antibodies to influenza hemagglutinin
SA520420332B1 (ar) الأجسام المضادة لمكون مضاد للمتمم وطرق استخدامها
HK1254861A1 (zh) 抗lag3抗体及其用途
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2018003702A (es) Vectores del factor viii del virus adenoasociado, particulas viricas asociadas y formulaciones terapeuticas que las comprenden.
EA201990059A1 (ru) Фосфорамидаты для лечения вируса гепатита b
MX2022000879A (es) Vacuna viral terapeutica.
PH12015502164A1 (en) Flavivirus neutralizing antibodies and methods of use thereof
GEP20257804B (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
Valdez et al. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains
EP3830114A4 (en) USE OF INTERLEUKIN-7 AND CHIMERA ANTIGEN RECEPTOR (CAR) IMMUNE EFFECTOR CELLS FOR TUMOR TREATMENT
SA520420568B1 (ar) جين متماثل من الديسموتاز فائق الأكسيد المستقر واستخداماته (sod)
WO2020028719A3 (en) Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer
WO2019147867A9 (en) Human antibodies to influenza hemagglutinin
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
ZA202103263B (en) Placenta-derived allogeneic car-t cells and uses thereof
EA201991096A1 (ru) Ингалируемая порошковая композиция, содержащая анти-il-13-антитело